This is the authors' abstract. We don't add key points for this paper.
In a clinical study we found that patients with primary node negative breast cancer whose tumors showed high expression of H-ras had a significantly better prognosis than patients whose carcinomas did not. In the present study, these tissue specimens showed no H-ras gene mutation. The rate of gene amplification was 5% and did not correlate with the level of H-ras expression. These data indicate that increased expression and not amplification of the H-ras gene is valuable, if H-ras has a favorable role with respect to clinical outcome. This might be a general protective reaction as long as no mutation event has occurred in the H-ras gene.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Schöndorf et al. (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: